Correvio Pharma (CORV) Issues Earnings Results, Beats Estimates By $0.01 EPS

Correvio Pharma (NASDAQ:CORV) issued its earnings results on Wednesday. The company reported ($0.18) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.01, MarketWatch Earnings reports. Correvio Pharma had a negative return on equity of 294.35% and a negative net margin of 68.98%.

Shares of CORV opened at $3.90 on Thursday. The stock has a market cap of $152.88 million, a price-to-earnings ratio of -4.33 and a beta of 0.67. Correvio Pharma has a 12 month low of $1.46 and a 12 month high of $5.24. The company has a debt-to-equity ratio of 4.02, a quick ratio of 3.46 and a current ratio of 4.05.

Several institutional investors and hedge funds have recently modified their holdings of CORV. BlackRock Inc. acquired a new position in shares of Correvio Pharma during the fourth quarter worth about $39,000. Worth Venture Partners LLC acquired a new position in shares of Correvio Pharma during the third quarter worth about $173,000. Columbia Pacific Advisors LLC acquired a new position in shares of Correvio Pharma during the fourth quarter worth about $251,000. Essex Investment Management Co. LLC acquired a new position in shares of Correvio Pharma during the fourth quarter worth about $333,000. Finally, ARS Investment Partners LLC increased its position in shares of Correvio Pharma by 19.7% during the fourth quarter. ARS Investment Partners LLC now owns 333,855 shares of the company’s stock worth $831,000 after acquiring an additional 54,915 shares during the last quarter. Institutional investors own 41.88% of the company’s stock.



A number of research analysts recently weighed in on the company. B. Riley assumed coverage on Correvio Pharma in a report on Tuesday, December 4th. They issued a “buy” rating and a $7.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.50 target price on shares of Correvio Pharma in a report on Monday, January 14th.

WARNING: This report was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://dakotafinancialnews.com/2019/03/14/correvio-pharma-corv-issues-earnings-results-beats-estimates-by-0-01-eps.html.

Correvio Pharma Company Profile

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

Featured Article: Why is the conference call important?

Earnings History for Correvio Pharma (NASDAQ:CORV)

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.